Olga Amengual

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2966357/publications.pdf

Version: 2024-02-01

72	2,229	279798 23	223800 46
papers	citations	h-index	g-index

74	74	74	1850
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested caseâ€“control study. Rheumatology International, 2022, 42, 1939-1946.	3.0	9
2	Aberrant functional connectivity between anterior cingulate cortex and left insula in association with therapeutic response to biologics in inflammatory arthritis. Seminars in Arthritis and Rheumatism, 2022, 55, 151994.	3.4	5
3	Pathogenesis of antiphospholipid syndrome. , 2021, , 555-564.		0
4	COVID-19 pandemic in Japan. Rheumatology International, 2021, 41, 1-5.	3.0	51
5	Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study. Rheumatology, 2021, 60, 1331-1337.	1.9	17
6	New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome. European Journal of Rheumatology, 2021, 8, 93-99.	0.6	6
7	Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
8	Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. Modern Rheumatology, 2020, 30, 116-124.	1.8	3
9	Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. Autophagy, 2020, 16, 946-955.	9.1	26
10	B cells targeting therapy in the management of systemic lupus erythematosus. Immunological Medicine, 2020, 43, 16-35.	2.6	21
11	Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus. Lupus, 2020, 29, 1238-1247.	1.6	8
12	Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease. Journal of Bone and Mineral Metabolism, 2020, 38, 581-588.	2.7	11
13	Myofascia-dominant involvement on whole-body MRI as a risk factor for rapidly progressive interstitial lung disease in dermatomyositis. Rheumatology, 2020, 59, 1734-1742.	1.9	13
14	Disseminated subcutaneous nodules and destructive polyarthritis. BMJ: British Medical Journal, 2019, 365, l1344.	2.3	2
15	Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1134-1143.	3.8	27
16	Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss. Clinical Immunology, 2019, 203, 37-44.	3.2	15
17	OP0213â€…MYOFASCIA-DOMINANT: INFLAMMATION DETECTED ON WHOLE BODY MRI PREDICTS RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE IN PATIENTS WITH DERMATOMYOSITIS. , 2019, , .		0
18	Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus. Rheumatology, 2019, 58, 645-649.	1.9	19

#	Article	IF	Citations
19	Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. Rheumatology, 2019, 58, 969-974.	1.9	24
20	Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome. Thrombosis Research, 2018, 164, 63-68.	1.7	7
21	Antiphospholipid syndrome, â€œthe best prophet of the futureâ€• Modern Rheumatology, 2018, 28, 409-416.	1.8	17
22	Firstâ€Line, Nonâ€Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Antiâ€“Î²2‹sub›2‹/sub›â€Glycoprotein I Domain I and Antiâ€“Phosphatidylserine/Prothrombin Complex Antibodies Tests. Arthritis Care and Research, 2018, 70, 627-634.	3.4	52
23	Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus. Modern Rheumatology, 2018, 28, 865-871.	1.8	12
24	Effectiveness of whole-body magnetic resonance imaging for the efficacy of biologic anti-rheumatic drugs in patients with rheumatoid arthritis: A retrospective pilot study. Modern Rheumatology, 2017, 27, 953-960.	1.8	8
25	Effectiveness of a Medical English Course on Communication Abilities of Graduate Medical Students. Medical Science Educator, 2017, 27, 209-216.	1.5	0
26	Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 47-69.	0.1	0
27	Current trends in medical English education and the Japan College of Rheumatology International School. Modern Rheumatology, 2017, 27, 1101-1105.	1.8	5
28	How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores. Current Rheumatology Reports, 2017, 19, 51.	4.7	20
29	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
30	Disease and Risk Measurement Criteria in Antiphospholipid Syndrome. , 2017, , 189-199.		0
31	Complement and thrombosis in the antiphospholipid syndrome. Autoimmunity Reviews, 2016, 15, 1001-1004.	5.8	46
32	Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. Thrombosis Research, 2016, 146, 1-6.	1.7	23
33	Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome. Rheumatology, 2016, 55, 1403-1411.	1.9	23
34	Ribophorin II is involved in the tissue factor expression mediated by phosphatidylserine-dependent antiprothrombin antibody on monocytes. Rheumatology, 2016, 55, 1117-1126.	1.9	2
35	Pathogenesis of Antiphospholipid Syndrome. , 2016, , 487-494.		2
36	Ras Guanine Nucleotideâ€“Releasing Protein 4 Is Aberrantly Expressed in the Fibroblastâ€like Synoviocytes of Patients With Rheumatoid Arthritis and Controls Their Proliferation. Arthritis and Rheumatology, 2015, 67, 396-407.	5.6	16

#	Article	IF	Citations
37	Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. Lupus, 2015, 24, 1135-1142.	1.6	48
38	The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus, 2015, 24, 3-9.	1.6	41
39	The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology, 2015, 54, 39-44.	1.9	104
40	Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies. Rheumatology International, 2014, 34, 1225-1230.	3.0	8
41	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Reviews, 2014, 13, 917-930.	5.8	224
42	Phospholipid scramblase 1 expression is enhanced in patients with antiphospholipid syndrome. Modern Rheumatology, 2013, 23, 81-88.	1.8	12
43	Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology, 2013, 52, 1775-1784.	1.9	25
44	Phospholipid scramblase 1 expression is enhanced in patients with antiphospholipid syndrome. Modern Rheumatology, 2013, 23, 81-88.	1.8	7
45	Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. European Journal of Clinical Investigation, 2012, 42, 1126-1135.	3.4	36
46	Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis and Rheumatism, 2012, 64, 504-512.	6.7	227
47	Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome. Current Vascular Pharmacology, 2011, 9, 606-618.	1.7	9
48	Anti-Î²2 glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: a case-controlled study. Journal of Reproductive Immunology, 2010, 84, 95-99.	1.9	17
49	Increased Expression of Phospholipid Scramblase 1 in Monocytes from Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 1639-1645.	2.0	16
50	The effects of phosphatidylserineâ€dependent antiprothrombin antibody on thrombin generation. Arthritis and Rheumatism, 2009, 60, 2457-2467.	6.7	41
51	Antiprothrombin Antibody Testing: Detection and Clinical Utility. Seminars in Thrombosis and Hemostasis, 2008, 34, 335-339.	2.7	32
52	Etiopathology of the Antiphospholipid Syndrome. , 2008, , 521-535.		0
53	Antiphospholipid antibodies: Lessons from the bench. Journal of Autoimmunity, 2007, 28, 129-133.	6.5	46
54	A polymorphism in human platelet antigen 6b and risk of thrombocytopenia in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 2803-2805.	6.7	3

#	Article	IF	Citations
55	Genetics of Antiphospholipid Syndrome. , 2006, , 521-531.		1
56	Pathophysiology of the antiphospholipid syndrome: roles of anticardiolipin antibodies in thrombosis and fibrinolysis. APLAR Journal of Rheumatology, 2006, 9, 377-386.	0.2	2
57	Research around Î²2-glycoprotein I: A major target for antiphospholipid antibodies. Autoimmunity, 2005, 38, 377-381.	2.6	21
58	The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-Â2Glycoprotein I antibodies. International Immunology, 2004, 16, 1633-1641.	4.0	115
59	Antiprothombin antibodies and the diagnosis of antiphospholipid syndrome. Clinical Immunology, 2004, 112, 144-149.	3.2	27
60	Antiprothrombin antibodiesâ€"are they worth assaying?. Thrombosis Research, 2004, 114, 533-538.	1.7	40
61	Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. Clinical Rheumatology, 2004, 23, 218-222.	2.2	30
62	Nicked Â2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood, 2004, 103, 3766-3772.	1.4	54
63	Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis and Rheumatism, 2003, 48, 886-895.	6.7	65
64	Antiphospholipid Syndrome and Atherosclerosis. , 2001, , 279-287.		1
65	â€œEndotheliologyâ€•in Antiphospholipid Antibodies. , 2001, , 289-296.		0
66	An evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of arterial thrombosis in patients with the antiphospholipid syndrome. Arthritis and Rheumatism, 2000, 43, 1655-1656.	6.7	11
67	Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome. Arthritis and Rheumatism, 1999, 42, 2606-2611.	6.7	35
68	Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. Arthritis and Rheumatism, 1998, 41, 800-807.	6.7	124
69	IgG2 restriction of anti-Î²2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: Comment on the article by Sammaritano et al. Arthritis and Rheumatism, 1998, 41, 1513-1514.	6.7	16
70	The Role of the Tissue Factor Pathway in the Hypercoagulable State in Patients with the Antiphospholipid Syndrome. Thrombosis and Haemostasis, 1998, 79, 276-281.	3.4	256
71	Up-Regulated Tissue Factor Expression in Antiphospholipid Syndrome. Thrombosis and Haemostasis, 1997, 77, 222-223.	3.4	32
72	Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis. Clinical and Experimental Rheumatology, 0, , .	0.8	3